Opto Circuit’s subsidiary to launch its first Sirolimus Drug Eluting Stent

10 Sep 2012 Evaluate

Opto Circuit’s subsidiary, Opto Eurocor Healthcare, has launched its first Sirolimus Drug Eluting Stent (DES), E-MAGIC plus on receipt of Drug Controller General of India (DCGI) license to sell and market products in India. With the launch of E-MAGIC Plus, Opto Circuits becomes one of the few global players to offer DES products with choice of two drugs coatings.

E-MAGIC plus consists of a balloon expandable intra coronary chromium stent pre-mounted on a custom balloon delivery system with a Sirolimus coating (also known as Rapamycin), into the arterial wall. Sirolimus helps control excess growth of cells and allows the artery to heal. Further, E-magic plus stent has an extra edge with soft tip technology to provide smooth access to the lension site ensuring minimal trauma to the vessel wall.

The Sirolimus DES market is estimated to be worth of Rs 800 crore in India. E-Magic has been developed indigenously in India and with DCGI mark; the company can market and sell in India. Meanwhile, the DGCI approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East.

Opto Circuits (I) Share Price

1.78 0.00 (0.00%)
23-May-2022 18:01 View Price Chart
Peers
Company Name CMP
Poly Medicure 2581.85
Hemant Surgical Inds 136.50
Nureca Ltd. 273.50
Prevest Denpro 540.00
Centenial Surgical 125.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.